Encompass Wealth Advisors LLC Grows Position in Johnson & Johnson (NYSE:JNJ)

Encompass Wealth Advisors LLC raised its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 2.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,619 shares of the company’s stock after acquiring an additional 149 shares during the period. Encompass Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $1,081,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. GHP Investment Advisors Inc. increased its position in shares of Johnson & Johnson by 1.9% during the 3rd quarter. GHP Investment Advisors Inc. now owns 44,641 shares of the company’s stock valued at $7,293,000 after purchasing an additional 828 shares during the last quarter. Arlington Partners LLC increased its position in shares of Johnson & Johnson by 5.4% during the 3rd quarter. Arlington Partners LLC now owns 16,626 shares of the company’s stock valued at $2,716,000 after purchasing an additional 851 shares during the last quarter. LS Investment Advisors LLC increased its position in shares of Johnson & Johnson by 13.3% during the 3rd quarter. LS Investment Advisors LLC now owns 15,627 shares of the company’s stock valued at $2,552,000 after purchasing an additional 1,837 shares during the last quarter. Graybill Bartz & Assoc Ltd. increased its position in shares of Johnson & Johnson by 1.4% during the 3rd quarter. Graybill Bartz & Assoc Ltd. now owns 22,635 shares of the company’s stock valued at $3,698,000 after purchasing an additional 323 shares during the last quarter. Finally, Mitchell Capital Management Co. increased its position in shares of Johnson & Johnson by 2.7% during the 3rd quarter. Mitchell Capital Management Co. now owns 33,283 shares of the company’s stock valued at $5,437,000 after purchasing an additional 861 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insiders Place Their Bets

In related news, CAO Robert J. Decker sold 16,928 shares of the business’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,707,775. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the transaction, the vice president now owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Robert J. Decker sold 16,928 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,707,775. The disclosure for this sale can be found here. In the last ninety days, insiders sold 277,886 shares of company stock worth $48,550,549. 0.35% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently commented on JNJ. Barclays initiated coverage on Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective on the stock. Raymond James reduced their price target on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. StockNews.com initiated coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Morgan Stanley reduced their price target on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 6th. Finally, Bank of America reduced their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Seven research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $182.42.

Johnson & Johnson Stock Down 0.6 %

Shares of NYSE JNJ opened at $172.36 on Wednesday. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The firm has a market capitalization of $450.63 billion, a PE ratio of 24.01, a price-to-earnings-growth ratio of 3.28 and a beta of 0.56. The firm has a fifty day simple moving average of $176.30 and a two-hundred day simple moving average of $171.39.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The business had revenue of $23.79 billion during the quarter, compared to analyst estimates of $23.44 billion. During the same period in the prior year, the business earned $2.60 EPS. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a $1.13 dividend. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 annualized dividend and a yield of 2.62%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.